Merck & Co. shares closed Friday's trading session with a significant gain, advancing 3.8% to $123.82, as investors digested a mix of promising clinical trial updates and corporate restructuring news. The pharmaceutical giant's stock was largely unchanged in after-hours activity, setting the stage for a closely watched Monday opening.
Oncology Pipeline Delivers Positive Readouts
The primary driver for the share price movement was a series of weekend data releases concerning Merck's flagship oncology asset, Keytruda (pembrolizumab). The company reported that in an adjuvant kidney cancer trial, the combination of Keytruda and Welireg (belzutifan) demonstrated a 28% reduction in the risk of disease recurrence or death compared to Keytruda plus a placebo. This study involved patients who had undergone a nephrectomy, or kidney removal. The U.S. Food and Drug Administration (FDA) has accepted Merck's supplemental filings for this combination and granted them a Priority Review designation, with a target action date of June 19, 2026.
Dr. Toni K. Choueiri of the Dana-Farber Cancer Institute, cited by Merck, characterized the findings as "an important step forward." Catherine Pietanza, a Merck executive, emphasized the distinct profile of the Keytruda-Welireg regimen in treating renal cell carcinoma.
Broadening Cancer Franchise Strength
Beyond kidney cancer, Merck highlighted robust late-stage results in other areas. In muscle-invasive bladder cancer, Keytruda combined with Padcev (enfortumab vedotin) – an antibody-drug conjugate developed with Pfizer and Astellas – showed a 47% reduction in event-free survival events and a 35% lower risk of death compared to standard chemotherapy followed by surgery for cisplatin-eligible patients. This data is now being prepared for submission to global regulators.
Furthermore, the company presented data in platinum-resistant recurrent ovarian cancer, where adding Keytruda to paclitaxel chemotherapy (with or without bevacizumab) resulted in a statistically significant improvement in overall survival. This regimen also recently received a positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) for a specific patient subset.
Vaccine Segment Faces Headwinds
Not all news was positive. Concurrently, Merck announced plans to eliminate approximately 150 positions at its Gardasil human papillomavirus (HPV) vaccine manufacturing site in North Carolina. The layoffs, scheduled for May, follow the company's decision to halt shipments of Gardasil to China last year amid softening global demand for the vaccine. This move underscores the ongoing challenges in the vaccine segment, attributed to weaker demand in China and evolving immunization guidelines in the United States, which have increased Merck's reliance on its oncology pipeline for growth.
Market Context and Investor Focus
The latest clinical data is critical for Merck as it seeks to maximize the commercial potential of Keytruda, its top-selling product, ahead of key patent expirations later this decade. Investors are keenly watching the company's ability to expand Keytruda's utility through new indications and strategic combinations. The positive kidney cancer results for the Keytruda-Welireg pairing represent a tangible step in that direction.
Analysts note, however, that the kidney cancer data is based on disease-free survival, with overall survival results still maturing. Additionally, combination therapies often come with higher rates of adverse events, which could influence real-world adoption by physicians. The immediate market focus will be on whether the momentum from Friday's rally extends into the new trading week, potentially fueled by these weekend updates and any further data presented at medical conferences.
The next fixed catalyst for Merck's stock is the FDA's decision on the Keytruda-Welireg combination for adjuvant renal cell carcinoma, expected by the June 19, 2026 deadline.
